

Webcast Alert: Isis Conference Call

November 5, 2002

CARLSBAD, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals (Nasdaq: ISIS) announces the following Webcast:

What: Isis Pharmaceuticals Discusses Its Third-Quarter Financial Results.

When: Thursday, November 7, 2002 @ 5:30 am Pacific Time / 8:30 am Eastern Time

Where: <http://www.firstcallevents.com/service/ajwz369610280gf12.html>

How: Live over the Internet -- Simply log on to the web at the address above.

Contact: Karen Lundstedt of Isis Pharmaceuticals, Inc., +1-760-603-3880.

If you are unable to participate during the live webcast, the call will be archived on the Web site www.isispharm.com , or the address above.

Isis Pharmaceuticals, Inc. is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs. The company has commercialized its first product, Vitravene® (fomivirsen), to treat CMV-induced retinitis in AIDS patients. In addition, Isis has 13 antisense products in its development pipeline with two in late-stage development and six in Phase II human clinical trials. Affinitac™, an inhibitor of PKC-alpha, is in Phase III trials for non-small cell lung cancer, and alicaforsen (ISIS 2302), an ICAM-1 inhibitor, is in Phase III trials for Crohn's disease. Isis has a broad patent estate as the owner or exclusive licensee of more than 1,000 issued patents worldwide. Isis' GeneTrove™ division uses antisense to assist pharmaceutical industry partners in validating and prioritizing potential gene targets through customized services. Ibis Therapeutics™ is a division focused on the discovery of small molecule drugs that bind to RNA. Additional information about Isis is available at www.isispharm.com .

(Minimum Requirements to listen to broadcast: The Windows Media Player software, downloadable free from <http://www.microsoft.com/windows/windowsmedia/EN/default.asp> and at least a 28.8Kbps connection to the Internet. If you experience problems listening to the broadcast, send an email to webcastsupport@tfprn.com.)

Make Your Opinion Count - Click Here

<http://tbutton.prnewswire.com/pm/11690X45666358>

SOURCE Isis Pharmaceuticals, Inc.